Pilot Weight Loss Intervention With Dual GIP/GLP-1 Receptor Agonist Therapy in Patients With Endometrial Cancer and Obesity
Bose S (PI)
Summary
Memorial Sloan Kettering is conducting a pilot study evaluating weekly subcutaneous tirzepatide (2.5mg → 5mg) for weight management in stage I-III endometrial cancer patients undergoing chemotherapy. The study will assess feasibility (≥70% dose completion), GI adverse events, and changes in body composition, weight, and blood pressure over 24 weeks.
Clinical Significance
First study systematically evaluating GLP-1/GIP dual agonist therapy during active cancer treatment. Addresses the critical intersection of obesity and cancer, where weight management could improve chemotherapy tolerability and oncologic outcomes in one of the most obesity-associated malignancies.
İlgili Araştırma
Real-World Weight-Loss Outcomes in Weight-Reduced Patients Treated With Tirzepatide
This real-world study of 293 patients found that tirzepatide produced 10.3% total body weight loss i…
Glucagon-like Peptide-1 Receptor Agonists and Risk of Depression: A Systematic Review and Meta-Analysis
This comprehensive meta-analysis examined the relationship between GLP-1 receptor agonist use and de…
Tirzepatide/Semaglutide Weight Loss Intervention in Patients With Endometrial Cancer and Obesity
Memorial Sloan Kettering is conducting a pilot study evaluating tirzepatide (with semaglutide as alt…
Exposure-Adjusted Safety and Efficacy of GLP-1 and GLP-1/GIP Receptor Agonists for Weight Management and Type 2 Diabetes
This comprehensive analysis of FDA regulatory data across 14 medications and over 34,000 safety subj…